Riudavets Mariona, Wyplosz Benjamin, Ghigna Maria Rosa, Botticella Angela, Abdayem Pamela, Pradere Pauline, Kasraoui Ines, Roux Charles, Le Pechoux Cécile, Garcia Camilo, Planchard David
Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France.
Infectious Diseases Department, Hôpital Bicêtre-AP-HP, Le Kremlin Bicêtre, France.
JTO Clin Res Rep. 2022 Mar 31;3(5):100319. doi: 10.1016/j.jtocrr.2022.100319. eCollection 2022 May.
The use of immune checkpoint inhibitors (ICIs) has drastically transformed the therapeutic landscape in lung cancer. Special focus has been put on immune-related toxicity; however, infections can also seem during ICI treatment. Although rare, tuberculosis (TB) has been increasingly identified after ICIs, and it seems that the programmed cell death protein 1 and programmed death-ligand 1 pathway is directly involved in its pathophysiology. Here, we describe the case of a patient with advanced NSCLC who developed abdominal TB after 32 months of pembrolizumab and who remains in tumor remission 10 months after discontinuation of this drug. Routine screening for latent TB before ICI treatment is advised, with closer collaboration between infectious disease specialists and oncologists.
免疫检查点抑制剂（ICI）的应用极大地改变了肺癌的治疗格局。人们特别关注免疫相关毒性；然而，在ICI治疗期间也可能出现感染。尽管罕见，但ICI治疗后结核病（TB）的诊断越来越多，并且程序性细胞死亡蛋白1和程序性死亡配体1通路似乎直接参与其病理生理过程。在此，我们描述了1例晚期非小细胞肺癌（NSCLC）患者的病例，该患者在使用帕博利珠单抗32个月后发生腹部结核，在停用该药10个月后仍处于肿瘤缓解状态。建议在ICI治疗前对潜伏性结核进行常规筛查，传染病专家和肿瘤学家之间应加强协作。
